Scarica l'app Stockscreener
253.79
0.69%
-1.77
Dopo l'orario di chiusura:
253.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Johnson Johnson Borsa (JNJ) Ultime notizie
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance
Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn’s Disease Fistula Study - Yahoo
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal - Zacks Investment Research
Has Johnson & Johnson Stock Become A Different Bet? - Yahoo Finance
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally - TipRanks
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - Yahoo Finance
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - AOL.com
Zacks Investment Ideas feature highlights: Intuitive Surgical - Zacks Investment Research
Johnson & Johnson (NYSE:JNJ): Can Drug Advances Strengthen the S&P 500? - Kalkine Media
What Does Johnson & Johnson (JNJ) News Mean For Its Growth Case? - Simply Wall Street
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law - The National Law Review
Should You Invest in This Dividend King on the Dip? - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Former J&J site cleared for £31m redevelopment - BBC
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool
Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more - Seeking Alpha
Breakfast News: Week in Review - The Motley Fool
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
3 Companies Raising Guidance This Earnings Season - Zacks Investment Research
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research
Johnson & Johnson reports mixed Q3 earnings - Healthcare Brew
Where Could Johnson & Johnson’s Next Growth Come From? - Trefis
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Johnson & Johnson CFO taps internal investment for medtech growth - CFO Dive
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView
The Open Question Under Johnson & Johnson Stock’s Price - Trefis
Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St.
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges - Zacks Investment Research
Johnson & Johnson Reports Q3 2026 Results, Raises Full-Year Guidance - VisionMonday.com
Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint - MassDevice
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
Johnson & Johnson: Keep Calm And Hold On (NYSE:JNJ) - Seeking Alpha
J&J’s medtech business slows again in Q3 - MedTech Dive
Johnson & Johnson shares fall following earnings - CNBC
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem - Barron's
Why Johnson & Johnson Stock Dropped Today - The Motley Fool
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth - Morningstar
Why Johnson & Johnson Stock Dropped Today - Yahoo Finance
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):